| Literature DB >> 1358234 |
M H Giaffer1, C D Holdsworth, J E Lennard-Jones, C A Rodrigues, P B McIntyre, S Manjunatha, J H Baron, I G Barrison, R J Polson, A M Hoare.
Abstract
The efficacy of two doses of balsalazide for the maintenance of remission in patients with ulcerative colitis was compared in a double-blind multicentre trial. Sixty-five patients received a 2 g daily dose, and 68 a 4 g dose. The patient groups were similar at entry for sex, age, and disease distribution. Clinical assessment was carried out at 3-monthly intervals, with sigmoidoscopy, rectal biopsy, and blood tests on entry and at 26 and 52 weeks. Clinical relapse over twelve months was significantly less common on the 4 g dose (36%), than on the 2 g dose (55%), P less than 0.01. There were eight withdrawals on 2 g daily and 13 on 4 g daily, six and nine respectively being mainly due to gastrointestinal intolerance. It is concluded that balsalazide is a well-tolerated drug, and is effective for the maintenance of remission in patients with ulcerative colitis, the optimal dose being greater than 2 g daily.Entities:
Mesh：
Substances：
Year: 1992 PMID： 1358234 DOI： 10.1111/j.1365-2036.1992.tb00561.x
Source DB: PubMed Journal: Aliment Pharmacol Ther ISSN： 0269-2813 Impact factor: 8.171